PMID- 34009416
OWN - NLM
STAT- MEDLINE
DCOM- 20220217
LR  - 20220217
IS  - 1433-8726 (Electronic)
IS  - 0724-4983 (Linking)
VI  - 39
IP  - 11
DP  - 2021 Nov
TI  - Can serum endoglin be used to improve the diagnostic performance in prostate 
      cancer?
PG  - 4135-4142
LID - 10.1007/s00345-021-03714-5 [doi]
AB  - PURPOSE: New biomarkers may contribute to avoid unnecessary biopsies resulting 
      from the suboptimal performance of prostate-specific antigen (PSA) testing. This 
      study aimed to assess serum endoglin as a prostate cancer (PCa) diagnostic tool 
      among biopsy candidates. METHODS: A total of 262 consecutive patients referred 
      for prostate biopsy based on abnormal digital rectal examination and/or elevated 
      total PSA (tPSA) who had serum endoglin assessed by solid-phase enzyme-linked 
      immunosorbent assay were selected. Receiver operating characteristic curves were 
      used to compare the predictive accuracy of different combinations of biomarkers 
      to distinguish between PCa and benign prostatic conditions, and to identify 
      cut-offs that maximize the ability of endoglin to rule out patients for biopsy 
      (highest sensitivities). RESULTS: Serum endoglin levels were higher in patients 
      with PCa (median: 7.86 vs. 5.88 pg/mL, P < 0.001). Among patients with baseline 
      tPSA </= 10 ng/mL the area under the curve was 0.69 for endoglin. Approximately 
      one-quarter of the patients had serum endoglin < 4.92 ng/mL (sensitivity: 90.3%; 
      specificity: 32.8%), and the probability of PCa varied from 37.7% before testing 
      to 15.2% among those with low endoglin levels [negative predictive value 
      (NPV) = 84.8%]. When restricting the analyses to patients with free/total PSA 
      ratio > 0.25, the probability of cancer was less than 5% among those with serum 
      endoglin < 6.04 ng/mL (sensitivity: 93.8%; specificity: 56.1%), corresponding to 
      a NPV of 95.8%; this could allow sparing approximately 40% of patients from 
      biopsy. CONCLUSIONS: Serum endoglin may be useful in clinical practice to 
      distinguish between PCa and non-cancer patients among prostatic biopsy 
      candidates.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Pina, Francisco
AU  - Pina F
AUID- ORCID: 0000-0003-3523-1661
AD  - S. Joao University and Hospital Center-Urology, Porto, Portugal.
AD  - Lapa Hospital-Urology, Porto, Portugal.
FAU - Ferro, Ana
AU  - Ferro A
AD  - Departamento de Ciencias da Saude Publica e Forenses e Educacao Medica, Faculdade 
      de Medicina da Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319, 
      Porto, Portugal.
AD  - EPIUnit, Instituto de Saude Publica, Universidade do Porto, Porto, Portugal.
FAU - Botelho, Francisco
AU  - Botelho F
AD  - S. Joao University and Hospital Center-Urology, Porto, Portugal.
FAU - Manso, Margarida
AU  - Manso M
AD  - S. Joao University and Hospital Center-Urology, Porto, Portugal.
AD  - Department of Surgery and Physiology, University of Porto Medical School, Porto, 
      Portugal.
FAU - Dias, Nuno
AU  - Dias N
AD  - S. Joao University and Hospital Center-Urology, Porto, Portugal.
AD  - Department of Surgery and Physiology, University of Porto Medical School, Porto, 
      Portugal.
FAU - Figueiredo, Gabriela
AU  - Figueiredo G
AD  - S. Joao University and Hospital Center-Clinical Pathology, Porto, Portugal.
FAU - Pereira, Pedro
AU  - Pereira P
AUID- ORCID: 0000-0001-8465-7330
AD  - S. Joao University and Hospital Center-Pathology, Porto, Portugal.
FAU - Dinis, Paulo
AU  - Dinis P
AUID- ORCID: 0000-0003-2893-5492
AD  - S. Joao University and Hospital Center-Urology, Porto, Portugal.
AD  - Department of Surgery and Physiology, University of Porto Medical School, Porto, 
      Portugal.
FAU - Barros, Henrique
AU  - Barros H
AUID- ORCID: 0000-0003-4699-6571
AD  - Departamento de Ciencias da Saude Publica e Forenses e Educacao Medica, Faculdade 
      de Medicina da Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319, 
      Porto, Portugal.
AD  - EPIUnit, Instituto de Saude Publica, Universidade do Porto, Porto, Portugal.
FAU - Lunet, Nuno
AU  - Lunet N
AUID- ORCID: 0000-0003-1870-1430
AD  - Departamento de Ciencias da Saude Publica e Forenses e Educacao Medica, Faculdade 
      de Medicina da Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200-319, 
      Porto, Portugal. nlunet@med.up.pt.
AD  - EPIUnit, Instituto de Saude Publica, Universidade do Porto, Porto, Portugal. 
      nlunet@med.up.pt.
LA  - eng
PT  - Journal Article
DEP - 20210519
PL  - Germany
TA  - World J Urol
JT  - World journal of urology
JID - 8307716
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Endoglin)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Endoglin/*blood
MH  - Humans
MH  - Male
MH  - Predictive Value of Tests
MH  - Prostatic Neoplasms/*blood/*diagnosis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Diagnosis
OT  - Endoglin
OT  - Prostatic neoplasms
EDAT- 2021/05/20 06:00
MHDA- 2022/02/19 06:00
CRDT- 2021/05/19 12:40
PHST- 2021/01/08 00:00 [received]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2022/02/19 06:00 [medline]
PHST- 2021/05/19 12:40 [entrez]
AID - 10.1007/s00345-021-03714-5 [pii]
AID - 10.1007/s00345-021-03714-5 [doi]
PST - ppublish
SO  - World J Urol. 2021 Nov;39(11):4135-4142. doi: 10.1007/s00345-021-03714-5. Epub 
      2021 May 19.